Novogene is a global leader in genomic services, providing extensive next-generation sequencing (NGS) solutions to academic, clinical, and commercial research institutions. When engaging with a service provider of this scale, understanding the contractual framework is essential for ensuring project success, data integrity, and compliance. This guide outlines the key components typically found in a Novogene NGS service agreement.
The foundation of any NGS contract is the definition of the project scope. This includes the specific type of sequencing (e.g., WGS, WES, RNA-Seq, or Amplicon sequencing), the required depth of coverage, read length, and the expected yield of raw data. The contract documents these technical parameters to ensure that both the service provider and the client are aligned on the expected output before the physical samples are processed.
Novogene maintains rigorous quality control (QC) standards for incoming samples. The contractual agreement usually mandates that clients adhere to strict guidelines regarding DNA/RNA quantity, purity (A260/A280 ratios), and integrity (RIN scores). A key aspect of the contract is the "Sample QC" phase. If samples do not meet the specified requirements, the contract typically stipulates that the client must be notified. The agreement will define whether the client chooses to proceed at their own risk or provide replacement samples.
A significant portion of the NGS agreement details the delivery of results. This includes the bioinformatics analysis pipeline that will be applied to the raw sequence data. Standard contracts often cover:
The contract provides an estimated turnaround time (TAT) for the project, which usually begins once the samples have passed the initial QC. While these timelines are estimates rather than absolute guarantees, they provide a framework for project management. The agreement also addresses liability, usually limiting the provider's responsibility to re-sequencing the samples in the event of technical failure, rather than assuming liability for the downstream research implications or loss of potential discovery.
Novogene contracts contain standard clauses regarding intellectual property (IP). Typically, the sequencing data generated from the client's samples remains the property of the client. However, it is vital to check the terms regarding the provider's ability to use aggregated, de-identified metadata for process improvement or internal research, provided that it does not disclose sensitive client information or specific study results.
Depending on the nature of the research, the contract may reference compliance with international standards such as ISO certifications or CAP/CLIA guidelines. For projects involving human subject data, the contract will include provisions for data privacy, compliance with regional regulations (such as GDPR), and data storage policies. Clients should ensure their internal institutional review board (IRB) requirements are met prior to signing the agreement.
Every commercial contract includes clauses regarding how disputes are settled and how the project might be terminated. This includes provisions for cancellation fees if the client chooses to pull the project after sample processing has begun, as well as the procedure for invoicing if the project is completed in stages.
Before finalizing a contract with Novogene, it is recommended that the Principal Investigator (PI) or the authorized project lead clarifies any ambiguity in the "Statement of Work." Ensure that the coverage depth is sufficient for the study's statistical power, and confirm the method of raw data delivery to ensure compatibility with your local server infrastructure. By clearly understanding the terms of the service agreement, researchers can mitigate risks and ensure a smooth workflow from sample submission to data analysis.
